Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > T2 Biosystems Raises $15 Million in Series C Financing

Abstract:
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.

T2 Biosystems Raises $15 Million in Series C Financing

Cambridge, MA | Posted on May 25th, 2010

Physic Ventures led the round, joined by new investors Arcus Ventures, RA Capital, Camros Capital, WS Investments and existing investors, Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners and Partners Healthcare. T2 Biosystems previously raised $10.8 million in a Series B financing in 2008.

T2 Biosystems is developing the next generation of clinical diagnostic solutions through its proprietary technology, which combines nanotechnology and the miniaturization of proven magnetic resonance (MR) technology to eliminate the need for extensive sample preparation and enable rapid, accurate and portable diagnostics. T2 Biosystems' strategy is to develop a robust pipeline of products using its proprietary technology to enable the performance of molecular and immunoassay diagnostics on a small bench-top instrument in decentralized settings, including hospitals, diagnostic laboratories and medical offices.

The company has completed a fully functional alpha version of the commercial bench-top instrument and has developed a broad set of assays that demonstrates sensitivity, specificity, dynamic range and the precision equal or superior to large, specialized central lab analyzers. The company plans to launch the first of its commercial products to improve care of immunocompromised patients and will be working with industry partners to develop diagnostic tests for additional applications and to further advance the platform.

"This successful financing underscores the significant breakthroughs and value created by our team over the past two years" said John McDonough, CEO and President of T2 Biosystems. "Our mission is to revolutionize diagnostic testing by dramatically improving patient care and reducing overall healthcare costs by enabling immediate, accurate diagnostic testing in nearly any setting. The funding will allow us to advance and commercialize our initial menu of diagnostic tests in the decentralized setting where our unique technical advantages will improve disease diagnosis and treatment."

"T2 Biosystems' MR technology represents a novel approach for portable diagnostics, and T2's progress to date has been impressive," said Stacy Feld, Director at Physic Ventures. "T2 Biosystems is a strong fit with Physic's thesis to accelerate the personalized health agenda by enabling rapid, precise clinical diagnosis, thereby improving patient outcomes and reducing healthcare costs. I look forward to working with the company's outstanding management team and strong syndicate of existing investors to help bring T2's technology to the marketplace."

In connection with this financing, Ms. Feld will join the Board of Directors of T2 Biosystems, which is comprised of Michael Cima, Ph.D., Professor of Engineering, Material Science & Engineering, MIT; Alan Crane, General Partner, Polaris Venture Partners; Michael Greeley, General Partner, Flybridge Capital Partners; Robert Langer, D. Sc., Institute Professor, MIT; Stanley N. Lapidus, Chairman, Helicos Biosciences Corporation; Douglas A. Levinson, PhD, Partner, Flagship Ventures; and John McDonough, T2 Biosystems, Chief Executive Officer.

####

About T2 Biosystems
T2 Biosystems is a private biotechnology company developing next-generation clinical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to eliminate extensive sample preparation and provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.t2biosystems.com.

About Physic Ventures
Physic Ventures is the first venture capital firm dedicated to investing in keeping people healthy by providing capital and expertise to science-based, consumer-driven health and sustainable living companies. The firm's strategy is to capitalize on major economic, social and political trends shaping the landscape of personal and planetary health, including the rapid migration toward a consumer-driven, prevention-oriented "self-care" paradigm. Physic Ventures is based in San Francisco, CA. For more information, please visit Physic Ventures' website at www.physicventures.com.

For more information, please click here

Contacts:
T2 Biosystems, Inc.
286 Cardinal Medeiros Avenue
Cambridge, MA 02141
Phone: 617-661-8282
Fax: 617-876-1608

Copyright © T2 Biosystems

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Physicists develop new recipes for design of fast single-photon gun Physicists develop high-speed single-photon sources for quantum computers of the future September 21st, 2017

GLOBALFOUNDRIES Unveils Vision and Roadmap for Next-Generation 5G Applications: Technology platforms are uniquely positioned to enable a new era of ‘connected intelligence’ with the transition to 5G September 20th, 2017

GLOBALFOUNDRIES Delivers Custom 14nm FinFET Technology for IBM Systems: Jointly developed 14HP process is world’s only technology that leverages both FinFET and SOI September 20th, 2017

GLOBALFOUNDRIES Introduces New 12nm FinFET Technology for High-Performance Applications September 20th, 2017

Investments/IPO's/Splits

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Nanometrics Announces Upcoming Investor Events August 3rd, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Nanomedicine

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Announcements

Physicists develop new recipes for design of fast single-photon gun Physicists develop high-speed single-photon sources for quantum computers of the future September 21st, 2017

GLOBALFOUNDRIES Delivers Custom 14nm FinFET Technology for IBM Systems: Jointly developed 14HP process is world’s only technology that leverages both FinFET and SOI September 20th, 2017

GLOBALFOUNDRIES Introduces New 12nm FinFET Technology for High-Performance Applications September 20th, 2017

Copper catalyst yields high efficiency CO2-to-fuels conversion: Berkeley Lab scientists discover critical role of nanoparticle transformation September 20th, 2017

Tools

Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017

Chemical hot spots: Scanning tunneling microscopy measurements identify active sites on catalyst surfaces September 7th, 2017

Phenom-World selects Deben to supply a tensile stage as an accessory to their range of desktop SEMs August 29th, 2017

New results reveal high tunability of 2-D material: Berkeley Lab-led team also provides most precise band gap measurement yet for hotly studied monolayer moly sulfide August 26th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotechnology

Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Magnetic cellular 'Legos' for the regenerative medicine of the future September 12th, 2017

How to draw electricity from the bloodstream: A one-dimensional fluidic nanogenerator with a high power-conversion efficiency September 11th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project